Q-omics provides the consensus-scored PITX3 profile across patient tissues and cancer cell-line models. PITX3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PITX3 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, PITX3 RNA expression shows 13,590 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and THCA as cancer lineages where PITX3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PITX3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PITX3 survival associations across molecular data types. PITX3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PITX3 RNA expression–survival associations across cancer types. High PITX3 expression shows unfavorable associations in ACC, LUAD, MESO, BLCA and LIHC, but favorable associations in LUSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PITX3 RNA expression.
This table summarizes PITX3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for PITX3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PITX3 shows lower tumor expression in KICH and KIRC and higher tumor expression in THCA, COAD, UCEC and LUSC. The THCA box plot shows higher PITX3 RNA expression in tumor versus normal tissue (log2 FC = +0.695, t-test p < 0.001).
This table shows molecular features associated with PITX3 in patient tissues and cancer cell lines. In patient samples, PITX3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PITX3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and SOFT_TISSUE.
